Clinical Trial Update: A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

View source ↗

Summary

Marketing approval granted for BioMarin's BMN 190 (cerliponase alfa) to treat CLN2 disease; the therapy is now approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cln2 Disease

Drugs mentioned

• BRINEURA (cerliponase alfa)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: CLN2 Disease | Status: APPROVED_FOR_MARKETING